The newly approved oral formulation features a smaller pill size in 1.5mg, 4mg, and 9mg strengths while maintaining the efficacy and safety profile of the previous oral semaglutide version.

Novo Nordisk, which makes the GLP-1 semaglutide medications Ozempic and Wegovy, announced that it’s rolling out an “Ozempic ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary Diffuspheretm technology designed to optimize local, controlled drug ...

NewHomeSource reports that sleep is now a wellness status symbol, prompting new home designs focused on optimizing sleep ...

Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the ...

Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the ...

Tyler McBride walked about his middle school classroom in rural Arkansas years ago during a period of silent reading as ...

Novo Nordisk announced that starting Monday, May 4, Ozempic® (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available ...

Novo said the relaunched Ozempic pills are as safe and effective as Rybelsus tablets, which contain the same main ingredient, semaglutide, though in a different formulation and dose structure.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference ...

ANY medication can trigger side effects – though these are often symptoms like nausea, sleepiness or dizzy spells. But some ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...